Transcriptomics

Dataset Information

0

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [treatments]


ABSTRACT: Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. Treatment-related toxicity limited the ability for participants to receive protocol-specified chemotherapy and HER2-targeted therapy in the TCHL Arm.

ORGANISM(S): Homo sapiens

PROVIDER: GSE130787 | GEO | 2019/05/08

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2019-05-08 | GSE130786 | GEO
2024-06-03 | GSE234519 | GEO
2015-10-06 | GSE66305 | GEO
2015-10-06 | GSE66398 | GEO
2018-10-16 | GSE116335 | GEO
| PRJNA541356 | ENA
2010-12-15 | GSE17630 | GEO
| PRJNA541359 | ENA
| PRJNA541358 | ENA
2019-06-21 | GSE83608 | GEO